STX

Shield Therapeutics PLC

Health Care First-pass screen £93m

340/1000 Overall fit

AI beneficiary 35% 30

Operating leverage 25% 50

Valuation 25% 30

Downside protection 15% 25

First-pass take

Shield is a pre-commercial specialty pharma company with zero AI exposure. Despite promising early US launch (100% Rx growth, 100m lives covered), the company is deeply loss-making (£19.3m loss on £1.5m revenue), burning ~£17m annually, with explicit going-concern warnings and only 12 months cash runway. Not a fit for stockemon strategy.

Flags

loss-makinggoing-concerncash-burnpre-revenueequity-dilutiveno-valuation-datamicro-capclinical-stage